

Vext Announces \$22.2 Million Credit Facility

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/

Credit facility composed of two secured term loans bearing interest at 7.5%. Will be used to retire current secured debt, which currently bears an average rate of 10%. All currency is presented in USD.

VANCOUVER, BC, July 8, 2022 /CNW/ - [Vext Science, Inc.](#) ("Vext" or the "Company") (CSE: VEXT) (OTCQX: VEXTF) a cannabinoid brand leader based in Arizona, leveraging its core expertise in extraction, manufacturing, cultivation and marketing to build a profitable multi-state footprint, today announced that it has entered into an agreement with a California-based lender for a \$22.2 million credit facility (the "Credit Facility"), which will be used to refinance current secured debt, and working capital for potential acquisitions, capital expenditures and general and administrative expenses.

Eric Offenberger, CEO of Vext stated, "This credit facility both lowers Vext's cost of capital, and gives us additional flexibility as we continue to execute our growth plans in Arizona and Ohio. The next 12 months are expected to be a period of growth for Vext. With a solid balance sheet, ongoing free cash flow, and access to relatively low cost, non-dilutive capital, we are in a position of strength to continue generating growth and profitability for shareholders."

Terms of Credit Facility

The Credit Facility is comprised of two term loans. The first, is a \$17.185 million 20-year first lien secured term loan, bearing interest of WSJ Prime + 2.75%, with a floor price of 6.25%. The second, is a \$5 million five-year second lien secured term loan, bearing interest at WSJ Prime + 2.75%, with a floor price of 6.25%.

Canaccord Genuity acted as a financial adviser to Vext in connection with the Credit Facility.

For more details, visit Vext's [investor website](#) or contact the IR team at investors@vextscience.com.

About Vext Science, Inc.

[Vext Science, Inc.](#) is a US-based Cannabis THC and Hemp cannabinoid products company manufacturing THC cartridges, concentrates, edibles and accessories under the Vapen™ Brand, and Hemp based products under the Pure Touch Botanicals brand as well as the Vapen CBD brand. Based in Arizona, Vext Science, Inc. has one of the leading THC concentrates, edibles, and distillate cartridge brands sold in most of the state's 100+ dispensaries. Herbal Wellness Center is one of Arizona's leading dispensaries and we execute all aspects of the cultivation, extraction, edibles infusion and manufacturing processes which insures a product of the highest quality and purity. Product quality and purity are core to our marketing strategy. Vext Science, Inc. is executing its business growth by leveraging experience and expertise in extractions, product manufacturing, and marketing to expand in the U.S. through revenue and profit-sharing joint venture partnerships. For more information visit our website at www.VextScience.com or connect with us on [LinkedIn](#) and [Twitter](#).

For more details on the Vapen brand:

Vapen website: VapenBrands.com

Instagram: [@vapen](#)

Facebook: [@vapenbrands](#)

COVID-19 Risk Factor

Vext may be impacted by business interruptions resulting from pandemics and public health emergencies, including those related to COVID-19. An outbreak of infectious disease, a pandemic, or a similar public health threat, such as the recent outbreak of COVID-19, or a fear of any of the foregoing, could adversely impact Vext by causing operating, manufacturing, supply chain, and project development delays and disruptions, labor shortages, travel, and shipping disruption and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how Vext may be affected if such a pandemic persists for an extended period of time, including as a result of the waiver of regulatory requirements or the implementation of emergency regulations to which Vext is subject. Although Vext has been deemed essential and/or has been permitted to continue operating its facilities in the states in which it operates during the pendency of the COVID-19 pandemic, there is no assurance that the Company's operations will continue to be deemed essential and/or will continue to be permitted to operate. Vext may incur expenses or delays relating to such events outside of its control, which could have a material adverse impact on its business, operating results, financial condition and the trading price of the Company's Common Shares.

Forward Looking Statements

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Vext's periodic filings with Canadian securities regulators. When used in this news release, words such as "will, could, plan, estimate, expect, intend, may, potential, believe, should," and similar expressions, are forward-looking statements.

Forward-looking statements may include, without limitation, statements related COVID-19, to future developments, the expected use of the Credit Facility and the business and operations of Vext.

Although Vext has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; being engaged in activities currently considered illegal under U.S. Federal laws; change in laws; reliance on management; requirements for additional financing; competition; hindered market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry and; regulatory or political change.

There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. Because of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. Vext disclaims any intention or obligation to update or revise such information, except as required by applicable law, and Vext does not assume any liability for disclosure relating to any other company mentioned herein.

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

Eric Offenberger
Chief Executive Officer
[844-211-3725](tel:844-211-3725)

SOURCE VEXT Science, Inc.

View original content: <http://www.newswire.ca/en/releases/archive/July2022/08/c7076.html>

%SEDAR: 00039389E

For further information: Jonathan Ross, Vext Investor Relations, jon.ross@loderockadvisors.com,
416-244-9851

CO: VEXT Science, Inc.

CNW 07:30e 08-JUL-22